Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Sasanlimab and Sacituzumab Govitecan for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of bladder cancer known as Non-Muscle Invasive Bladder Cancer (NMIBC). The study is investigating the effects of two treatments: Sasanlimab and Sacituzumab Govitecan. Sasanlimab is a type of medication called a monoclonal antibody, which is designed to help the immune system fight cancer. Sacituzumab Govitecan is another type of monoclonal antibody that targets cancer cells directly.

The purpose of this study is to evaluate how effective the combination of Sasanlimab and Sacituzumab Govitecan is in treating patients whose cancer has not responded to a previous treatment called BCG (Bacillus Calmette-Guérin). The study will observe patients over a period of time to see if the cancer responds to the treatment. Participants will receive the medications through injections and will be monitored regularly to assess their response to the treatment.

Throughout the study, doctors will check the patients' health and the status of their cancer at different intervals. The main goal is to see if the cancer is completely gone after three months of treatment. The study will also look at how long any positive effects last and monitor for any side effects. This research aims to provide more information on the potential benefits of using these medications together for treating this type of bladder cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, the first step involves an initial visit to the clinical trial site. During this visit, a healthcare professional will review the study procedures and answer any questions.

    A series of tests and assessments will be conducted to confirm eligibility. These may include blood tests, urine tests, and a review of medical history.

  2. Step 2

    Treatment initiation

    The treatment phase begins with the administration of the study medications. The first medication, sasanlimab, is given as a subcutaneous injection, which means it is injected under the skin.

    The second medication, sacituzumab govitecan, is administered as an intravenous infusion, meaning it is delivered directly into a vein through a drip.

  3. Step 3

    Treatment schedule

    The treatment involves regular administration of the medications. Sasanlimab is given once every three weeks, while sacituzumab govitecan is administered on days 1 and 8 of each 21-day cycle.

    This schedule continues for the duration of the study, unless there are reasons to stop the treatment, such as side effects or disease progression.

  4. Step 4

    Regular assessments

    Throughout the study, regular assessments are conducted to monitor health and response to treatment. These assessments include physical exams, blood tests, and imaging studies.

    Cystoscopy, a procedure to look inside the bladder, and urine cytology, a test to check for abnormal cells in the urine, are performed to evaluate the response to treatment.

  5. Step 5

    Follow-up visits

    Follow-up visits are scheduled at specific intervals to assess the effectiveness of the treatment and to monitor for any side effects.

    These visits occur at 3, 6, 12, 18, and 24 months after starting the treatment. The primary goal is to determine the complete response rate of the disease.

  6. Step 6

    End of study

    The study is expected to conclude by March 31, 2025. At the end of the study, a final assessment will be conducted to evaluate the overall health and treatment outcomes.

    Participants will receive information about the results of the study and any further steps that may be necessary for their care.

Who can join the trial?

14 criteria

  • Provide written informed consent, which means you understand the purpose of the study and agree to participate.
  • Be reliable and willing to be available for the entire duration of the study and follow the study procedures.
  • Have a confirmed diagnosis of BCG-unresponsive high-risk, non-muscle invasive urothelial carcinoma. This is a type of bladder cancer that has not responded to a treatment called BCG.
  • Have refused or are not eligible for a surgery called radical cystectomy, which involves removing the bladder.
  • Have a type of bladder cancer called urothelial carcinoma, which makes up at least 50% of the cancer cells.
  • Be at least 18 years old.
  • Have an ECOG performance status of 0-1, which means you are fully active or have some symptoms but do not need bed rest during the day.
  • Have adequate organ function, which includes:
    • A certain level of white blood cells, platelets, and hemoglobin (a protein in red blood cells).
    • Normal blood clotting ability.
    • Normal liver function.
    • Normal kidney function.
    • Have no other cancer diagnosis within the last 2 years, except for certain types of skin cancer and cervical cancer that have been treated.
    • Agree to avoid pregnancy or fathering children during the study and for 6 months after the last dose of study drugs. This includes:
      • Men must take precautions to avoid fathering children and not donate sperm.
      • Women of childbearing potential must have a negative pregnancy test and take precautions to avoid pregnancy. Women who cannot become pregnant are eligible.

Who cannot join the trial?

10 criteria

  • Patients with a history of severe allergic reactions to the study drugs cannot participate.
  • Patients who have received another investigational drug within the last 4 weeks are not eligible.
  • Patients with uncontrolled infections are excluded from the study.
  • Patients with other active cancers, except for non-muscle invasive bladder cancer, cannot join the study.
  • Patients who are pregnant or breastfeeding are not allowed to participate.
  • Patients with significant heart problems, such as heart failure or recent heart attack, are excluded.
  • Patients with severe liver or kidney disease cannot take part in the study.
  • Patients who have had major surgery within the last 4 weeks are not eligible.
  • Patients with a history of drug or alcohol abuse within the last 6 months are excluded.
  • Patients who are unable to comply with the study procedures are not allowed to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Sasanlimab

    is a type of medication that helps the body's immune system fight cancer. It works by blocking a specific protein that usually stops the immune system from attacking cancer cells. By blocking this protein, sasanlimab allows the immune system to better recognize and destroy cancer cells. In this trial, it is being used to treat bladder cancer that has not responded to other treatments.

  • Sacituzumab govitecan

    is a medication that combines an antibody with a chemotherapy drug. The antibody part of the medication helps it find and attach to cancer cells, while the chemotherapy part helps kill those cells. This combination allows the medication to deliver the chemotherapy directly to the cancer cells, which can help reduce the growth of the cancer. In this trial, sacituzumab govitecan is being used alongside sasanlimab to treat bladder cancer that has not responded to other treatments.

What is already known about the treatment

  • Sasanlimab

    Sasanlimab is administered as an injection, typically given under the skin. It is currently being studied in clinical trials for its potential use in treating non-muscle invasive bladder cancer that does not respond to BCG therapy. The medication works by targeting specific proteins on cancer cells, helping the immune system to recognize and destroy these cells. Sasanlimab is classified as an immunotherapy drug, which means it helps the body's immune system fight cancer.

  • Sacituzumab Govitecan

    Sacituzumab govitecan is given as an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. It is being investigated in clinical trials for its effectiveness in treating non-muscle invasive bladder cancer that is unresponsive to BCG treatment. This medication combines an antibody with a chemotherapy drug, allowing it to specifically target and kill cancer cells while minimizing damage to healthy cells. Sacituzumab govitecan is classified as an antibody-drug conjugate, a type of targeted cancer therapy.

Investigated diseases

Non-Muscle Invasive Bladder Cancer – This type of bladder cancer is characterized by cancerous cells that are confined to the inner layers of the bladder wall and have not spread into the muscle layer. It often begins with the formation of small tumors on the bladder lining. As the disease progresses, these tumors can grow in size and number, potentially leading to more severe symptoms. The progression of the disease can vary, with some cases remaining stable while others may become more aggressive. Monitoring is crucial to detect any changes in the disease's behavior. Regular follow-ups are necessary to manage the condition effectively.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-518486-10-00Protocol codeAPRO07-2022Estimated enrolment42 patientsSponsorAssociacio Per A La Recerca Oncologica

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.